


PHARMACEUTICAL 2023

BOMARIN®

BIOMARIN PHARMACEUTICAL INC Rank 101 of 446





PHARMACEUTICAL 2023





BIOMARIN PHARMACEUTICAL INC Rank 101 of 446

The relative strengths and weaknesses of BIOMARIN PHARMACEUTICAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOMARIN PHARMACEUTICAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 71% points. The greatest weakness of BIOMARIN PHARMACEUTICAL INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 198%, being 154% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,751,457
Cost of Goods Sold	483,669
Intangible Assets	534,768
Liabilities, Current	588,884
Liabilities, Non-Current	100,015
Other Assets	2,015,483
Other Compr. Net Income	-18,299
Other Expenses	-16,822
Other Liabilities	1,083,019
Other Net Income	15,984
Other Revenues	2,096,039
Property and Equipment	1,073,366
Research and Development	649,606
Selling, General and Administrative Expense	854,009

Output Variable	Value in 1000 USD
Assets	6,375,074
Liabilities	1,771,918
Expenses	1,970,462
Revenues	2,096,039
Stockholders Equity	4,603,156
Net Income	141,561
Comprehensive Net Income	132,412
Economic Capital Ratio	198%

